NeuroSearch A/S (NEUR) announces adjusted annual report 2013, after the Danish Business Authority has made a decision concerning the control of the company's annual report for the financial year 2012.
The adjustment does not affect neither the company's results, equity nor the net cash flows, while it is merely a question of reclassification of the sale of the Huntexil®project from revenue to gain from divestment of intellectual property in 2012 and 2013.
Outlook for 2014
In 2014, NeuroSearch still expects an operating loss at approximately DKK 10 million. The expectations do not take into account any losses or gains which may result from a potential sale of the remaining assets of the company.
Allan Andersen, CEO, mobile phone +45 4016 3864.
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S.